Bionomics IPO Presentation Deck

BNC210 is Potentially Well-Positioned in Post-Traumatic Stress Disorder restore Anti-depressant and anti-anxiety trends seen at earlier time points ✓Safety profile generall well tolerated Did not meet primary endpoint"; lower than expected exposure of liquid suspension formulation Bionomics NHA ✓New tablet formulation overcomes food effect of suspension formulation ✓ Achieved exposure target predicted from pharmacometric analysis ✓ Extended IP coverage Pharmacometric analysis of Phase 2 PTSD data ✓Predicted significant efficacy potential with adequate drug exposure achieved *Primary endpoint of CAPS-5 total symptom severity score at 12 weeks FDA Type C meeting with FDA ✓ FDA granted Fast Track designation in PTSD ATTUNE Study ✓ Phase 2b ATTUNE trial started in July 2021 ✓ Topline data expected 1H 2023 20

View entire presentation